CYTK241220C95000
- 0.35
- 0.000.00%
Cytokinetics Newsroom
FDA Accepts Cytokinetics' Application for Cardiovascular Drug
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $62 to $120
Cytokinetics Opens Enrollment for COMET-HF Phase 3 Trial
Express News | Cytokinetics Announces Start of Comet-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), PTC Therapeutics (PTCT) and Vir Biotechnology (VIR)
Insider Sale: President & CEO of $CYTK (CYTK) Sells 5,000 Shares
Cytokinetics to Participate in December Investor Conferences
Optimistic Outlook for Cytokinetics Amidst Promising Aficamten Developments and Regulatory Progress
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Analyst Ratings
Express News | Cytokinetics Shares Down 1.2% After FDA Grants Standard Review for Co's Heart Disease Drug
Promising Prospects for Cytokinetics: Aficamten's Strong Phase 3 Results and Strategic Bayer Collaboration Drive Buy Rating
Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy
Express News | Cytokinetics Inc - FDA Not Planning Advisory Committee Meeting for Aficamten Nda
Express News | Cytokinetics Inc - Pdufa Target Action Date Set for September 26, 2025
Express News | Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)
Insider Sale: Director at $CYTK (CYTK) Sells 742 Shares
Calculating The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
FDA Accepts Bayer's Application for Label Expansion of Nubeqa